NERV

Minerva Neurosciences, Inc. (NERV) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (CNS) diseases. The company's lead candidate, roluperidone, is in development for negative symptoms of schizophrenia. Following a Complete Response Letter (CRL) from the FDA in February 2024, the company initiated a new Phase 3 confirmatory trial (C19) to address regulatory deficiencies. The first patient in the C19 trial was screened on March 31, 2026. The company has no approved products and generates no product revenue.

Key Financial Metrics

Cash Flow: Net cash used in operating activities was $5.4 million. Net cash used in investing activities was $45.3 million (primarily purchase of marketable securities). Net cash provided by financing activities was $1.1 million (warrant exercises).

Material Changes vs. Prior Period

• Significant Net Loss Increase: The net loss increased from $3.8 million in Q1 2025 to $125.4 million in Q1 2026. This is primarily driven by a $109.4 million non-cash loss due to the change in fair value of warrant liabilities established in an October 2025 private placement.
• Expense Growth: Total operating expenses rose to $16.7 million from $3.9 million.
  • R&D Expenses: Increased to $5.3 million (from $1.4 million) due to the initiation of the C19 Phase 3 trial.
  • G&A Expenses: Increased to $11.4 million (from $2.5 million), largely due to a $6.6 million non-cash stock-based compensation charge related to a settlement agreement with a former executive and higher professional fees.
• Liquidity Position: Cash and marketable securities increased significantly to $78.1 million from $17.4 million (cash only) in the prior year, following the October 2025 private placement which raised $80 million in gross proceeds.

Outlook, Risks, and Management Commentary

• Clinical Outlook: The C19 trial is designed to enroll 380 patients. Topline efficacy results are expected in the second half of 2027, with relapse assessment data in the second half of 2028.
• Liquidity: Management believes current resources ($78.2 million) are sufficient to meet operating commitments for at least 12 months. Additional capital may be required to complete development and commercialization.
• Key Risks:
  • Regulatory Uncertainty: No assurance that the C19 trial will succeed or that the FDA will approve roluperidone.
  • Warrant Liability Volatility: The company carries a significant warrant liability ($278.6 million) that is revalued quarterly, causing large non-cash fluctuations in net income.
  • Dilution: Outstanding Series A Preferred Stock and warrants could result in significant dilution upon conversion or exercise.
• Unusual Items: The $109.4 million loss on warrant liability and the $6.6 million stock-based compensation charge related to the Geoffrey Race settlement are significant non-cash items distorting GAAP net loss.

Investor Verification Checklist

• Warrant Liability Valuation: Verify the assumptions used to value the $278.6 million warrant liability, specifically the probability of achieving the Phase 3 milestone event.
• C19 Trial Progress: Monitor patient enrollment rates and any updates on the trial design relative to the FDA's requirements.
• Cash Burn Rate: Assess the sustainability of the $78.2 million cash balance against the projected costs of the C19 trial and commercialization preparations.
• Dilution Impact: Review the terms of the Series A Preferred Stock and Tranche A/B warrants to understand potential future share count increases.
• Non-GAAP Reconciliation: Review the Non-GAAP adjusted net loss of $(7.3) million to understand the core operational burn excluding the warrant liability volatility.